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Achieving tight glycemic control for the management of
type 1 diabetes is often associated with a heavy burden of
care, and frequent hypoglycemia. Closed loop insulin
delivery, or an “artificial pancreas”, represents a new
technological frontier for the management of type 1 dia-
betes which aims to overcome these difficulties. Rapid
advancement and improvement in the components of
closed loop systems (continuous glucose monitors, insu-
lin pumps, and mathematical algorithms) has been trans-
lated into numerous published reports demonstrating
effective glucose control in hospital studies, camps,
hotels, and most recently – in home studies. Most studies
to date have focused on overnight control due to the dif-
ficulties in managing glucose excursions from carbohy-
drate intake and exercise. We investigated the capability
of the Medtronic Hybrid Closed Loop (HCL) System in
managing glucose levels during both day and night. The
Medtronic HCL system consists of a Medtronic MiniMed
insulin pump, Medtronic MiniMed Enlite II glucose sen-
sor, Medtronic MiniMed Minilink REAL time sensor,
Medtronic MiniMed Translator, and an Android mobile
device with the HCL algorithm (proportional integrative
derivate minus insulin feedback and additional safety
parameters) software application installed. When using
the HCL, meal boluses are delivered manually using the
Android mobile device. All basal insulin delivery is con-
trolled by the algorithm. We present in-clinic pilot data
from 3 individuals with type 1 diabetes, incorporating
140 hours of closed loop management, over 5 days and
nights. A free living environment was simulated, with
free access to food, and exercise encouraged. For the
three participants, percent of time spent in target glucose
range (4 – 10mmol/L) was 81%, 62% and 73% respec-
tively. Including all data, the mean glucose was
8.74mmol/L, which corresponds to an HbA1c of approxi-
mately 7%. There were no hypoglycemic or adverse
events. We conclude that the Medtronic HCL system is
potentially effective and safe for the management of type
1 diabetes. Outpatient studies, with comparisons to sen-
sor augmented pump therapy with low glucose suspend
in a randomized cross-over trial are ongoing.
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